Search

Search Results

• MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA Guest Editor: Giancarlo Costaman

  Davide Matino, Paul Tieu, Dr., Antony Chan

  e2020001

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.001

  3227

  PDF: 1609

  HTML: 424

• SUCCESSFUL LONG TERM ERADICATION OF FACTOR VIII INHIBITOR IN PATIENTS WITH ACQUIRED HAEMOPHILIA A IN SAUDI ARABIA

  Galila F Zaher, Soheir S Adam

  e2012021

  2012-04-02

  https://doi.org/10.4084/mjhid.2012.021

  1282

  PDF: 893

  HTML: 3592

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2480

  PDF: 835

  HTML: 8815

  Efremov 1: 224

  Efremov 2: 184

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2098

  PDF: 1681

  HTML: 373

• SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

  Massimo Breccia, Giuliana Alimena

  e2014003

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.003

  3135

  PDF: 1214

  HTML: 3468

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1462

  PDF: 1135

  HTML: 268

• BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

  Stefano Molica

  e2025053

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.053

  1548

  PDF: 891

  HTML: 113

• TYROSINE KINASE INHIBITORS AND INTERFERON

  Maria Dimou, Panagiotis Panagiotidis

  e2014006

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.006

  2844

  PDF: 1434

  HTML: 3045

  Cover Letter: 205

• TYROSINE KINASE INHIBITORS AND PREGNANCY

  Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti

  e2014028

  2014-04-07

  https://doi.org/10.4084/mjhid.2014.028

  3531

  PDF: 1628

  HTML: 2673

• Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA

  Bhavya S Doshi, Valder R Arruda, Valder R Arruda

  e2020069

  2020-09-08

  https://doi.org/10.4084/mjhid.2020.069

  2038

  PDF: 1857

  HTML: 342

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4293

  PDF: 1479

  HTML: 3616

• Acquired Hemophilia A successfully treated with rituximab

  Giovanni D'Arena, Elvira Grandone, Matteo Nicola Dario Di Minno, Pellegrino Musto, Giovanni Di Minno

  e2015024

  2015-02-17

  https://doi.org/10.4084/mjhid.2015.024

  1925

  PDF: 1142

  HTML: 1455

  Figure 1: 173

• OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES

  Jon Salmanton-Garcia, Francesco Marchesi, Oliver A. Cornely, Jannik Stemler, Pierantonio Menna

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.022

  991

  PDF: 1167

  Suppl. Files: 144

  HTML: 66

• MUTATIONAL PROFILES OF F8 AND F9 IN A COHORT OF HAEMOPHILIA A AND HAEMOPHILIA B PATIENTS IN THE MULTI-ETHNIC MALAYSIAN POPULATION

  Maimiza Zahari, Siti Aishah Sulaiman, Zulhabri Othman, Yasmin Ayob, Faraizah Abd Karim, Rahman Jamal

  e2018056

  2018-09-01

  https://doi.org/10.4084/mjhid.2018.056

  2021

  PDF: 1052

  HTML: 705

  Figure 1: 153

  Figure 2: 165

• THROMBOTIC MICROANGIOPATHY IN HAEMATOPOIETIC CELL TRANSPLANTATION:AN UPDATE

  Evi Stavrou, Hillard Michael Lazarus

  e2010033

  2010-10-29

  https://doi.org/10.4084/mjhid.2010.033

  1574

  PDF: 1045

  HTML: 10446

• TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti

  e2014005

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.005

  3302

  PDF: 1463

  HTML: 3996

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4304

  PDF: 1487

  HTML: 1547

  Untitled: 225

• PROTEOLYTIC PROCESSING OF VON WILLEBRAND FACTOR BY ADAMTS13 AND LEUKOCYTE PROTEASES

  Stefano Lancellotti, Maria Basso, Raimondo De Cristofaro

  e2013058

  2013-09-01

  https://doi.org/10.4084/mjhid.2013.058

  3456

  PDF: 1157

  HTML: 24014

• Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series

  Shahrzad Zonoozi

  e2017004

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.004

  2903

  PDF: 985

  HTML: 1287

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2491

  PDF: 1980

  HTML: 199

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2440

  PDF: 783

  HTML: 1735

• PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER “GOOD RISK” ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASM

  Richard A. Larson, Michelle Le Beau

  e2011032

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.032

  2812

  PDF: 913

  HTML: 1867

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  1959

  PDF: 742

  HTML: 694

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277644

  PDF: 1788

  HTML: 3861

• OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE

  Grzegorz Helbig, Grazyna Bober, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien

  e2015003

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.003

  2210

  PDF: 1038

  HTML: 1981

  Characteristic of study group: 196

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1698

  PDF: 1654

  HTML: 796

• BACTERIAL PROFILE, ANTIBIOTIC SENSITIVITY AND RESISTANCE OF LOWER RESPIRATORY TRACT INFECTIONS IN UPPER EGYPT

  Gamal Agmy, Sherif Mohamed, Yaser Gad, Essam Farghally, Hamdy Mohammedin, Hebba Rashed

  e2013056

  2013-09-02

  https://doi.org/10.4084/mjhid.2013.056

  1993

  PDF: 1494

  HTML: 3604

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  2025

  PDF: 1111

  HTML: 179

• SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT

  Cecilia Monaldi, Sara De Santis, Manuela Mancini, Samantha Bruno, Michele Cavo, Simona Soverini

  e2021046

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.046

  1376

  PDF: 662

  HTML: 242

• ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

  Federico Lussana, Alessandro Rambaldi

  e2014065

  2014-10-20

  https://doi.org/10.4084/mjhid.2014.065

  2834

  PDF: 1223

  HTML: 2697

  Figure 1: 169

• CLINICAL CARE PATHWAY AND MANAGEMENT OF MAJOR BLEEDING ASSOCIATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS: A MODIFIED DELPHI CONSENSUS FROM SAUDI ARABIA AND UAE

  Abdulrahman Al Raizah, Fakhr Alayoubi, Galal Hassan Abdelnaby, Hazzaa Alzahrani, Majid Farraj Bakheet, Mohammed A Alskaini, Rasha Buhumaid, Sameer Al Awadhi, Sara Nooruddin Kazim, Thiagarajan Jaiganesh, Zohair Al Asiri

  e2024038

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.038

  2565

  PDF: 1173

  HTML: 103

• Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

  Nathalia Sena de Oliveira Silva, Gislaine Duarte, Samuel de Souza Medina, Guilherme Brasil Duffles Amarante, Carmino Antonio de Souza, Katia Borgia Barbosa Pagnano

  e2026001

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.001

  643

  PDF: 450

  Html: 75

• Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature

  Ekaterina Chelysheva, Sergey Aleshin, Evgenia Polushkina, Roman Shmakov, Igor Shokhin, Ghermes Chilov, Anna Turkina

  e2018027

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.027

  3153

  PDF: 984

  HTML: 354

• HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK

  Katleen de Gaetano Donati, Roberto Cauda, Licia Iacoviello

  e2010034

  2010-11-10

  https://doi.org/10.4084/mjhid.2010.034

  1811

  PDF: 794

  HTML: 3599

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  3890

  Suppl. Files: 1104

  PDF: 1061

  Html: 170

• COMPREHENSIVE REVIEW OF GENETIC AND EPIGENETICS REGULATION OF FETAL HEMOGLOBIN IN β-HEMOGLOBINOPATHIES: FROM MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS HbF Genetics in Anemia

  Yousef Saeed Mohammad Abu Za’ror, Joseph Bagi Suleiman, Fatima Azzahra Delmani, Jehad Farouq Alhmoud, Amer Mohammad Ayasreh, Sarah Ihsan Al-wendawi, Maryam Azlan

  e2026046

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.046

  299

  PDF: 240

  HTML: 17

• SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis

  Roberta Zanotti, Massimiliano Bonifacio, Ilaria Tanasi, Donatella Schena, Giovanni Orsolini, Morena Tebaldi, Lara Crosera, Francesca Mastropaolo, Elisa Olivieri, Dr. Patrizia Bonadonna

  e2021068

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.068

  1508

  PDF: 934

  HTML: 220

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  2064

  PDF: 1510

  HTML: 277

• THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY

  Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori

  e2012022

  2012-04-06

  https://doi.org/10.4084/mjhid.2012.022

  2168

  PDF: 876

  HTML: 1941

• HIV-ASSOCIATED VENOUS THROMBOEMBOLISM

  Michele Bibas, Gianluigi Biava, Andrea Antinori

  e2011030

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.030

  3859

  PDF: 1469

  HTML: 8510

• SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19

  Elisabetta Abruzzese, Luigia Luciano, Francesco D'Agostino, Malgorzata Monika Trawinska, Fabrizio Pane, Paolo de Fabritiis

  e2020031

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.031

  3250

  PDF: 1525

  HTML: 417

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

  Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

  e2024061

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.061

  2722

  PDF: 3194

  HTML: 368

• BISPHOSPHONATES IN LANGERHANS CELL HISTIOCYTOSIS: AN INTERNATIONAL RETROSPECTIVE CASE SERIES

  Deepak Chellapandian, Polyzois Makras, Gregory Kaltsas, Cor van den Bos, Lamia Naccache, Raajit Rampal, Anne-Sophie Carret, Sheila Weitzman, R. Maarten Egeler, Oussama Abla

  e2016033

  2016-07-01

  https://doi.org/10.4084/mjhid.2016.033

  3695

  PDF: 1242

  HTML: 1055

• THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association

  Katia Paciaroni, Selenia Campagna, Nicoletta Villiva', Enrico Maffini, Francesca Celesti, Attilio Tordi, Mariangela Lombardi, Giulia Dragonetti, Tommaso Caravita di Toritto

  e2025023

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.023

  1047

  PDF: 1039

  HTML: 93

• THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML

  Dr. Palmieri, Ilaria Del Principe, Dr. Maurillo, Prof. Venditti, Francesco Buccisano

  e2023051

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.051

  1596

  PDF: 801

  HTML: 160

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4306

  PDF: 1754

  HTML: 1106

• WHO HAS THERAPY-RELATED AML?

  Robert Gale, John M. Bennett, F. Owen Hoffman

  e2017025

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.025

  3108

  PDF: 4306

  HTML: 782

• PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA

  Anna Falanga, Laura Russo, Carmen J Tartari

  e2011068

  2011-12-21

  https://doi.org/10.4084/mjhid.2011.068

  1797

  PDF: 799

  HTML: 10229

  Figures 1,2,3: 172

• ROLE OF STEM CELL FACTOR IN THE REACTIVATION OF HUMAN FETAL HEMOGLOBIN

  Marco Gabbianelli, Ugo Testa

  e2009009

  2009-11-12

  1113

  PDF: 474

  HTML: 4476

• TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin

  Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni

  e2022073

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.073

  1228

  PDF: 976

  HTML: 209